(Q55887221)

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Behavioral treatment of generalized anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Treatment of Generalized Anxiety Disorder: Comparison of a New Beta-Blocking Drug (CGP361 A), Low-Dose Neuroleptic (Flupenthixol), and Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Generalised anxiety: a controlled treatment study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Anxiety management for persistent generalised anxiety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Alprazolam compared to clobazam and placebo in anxious outpatients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Comparison of withdrawal of buspirone and diazepam: a placebo controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Discontinuation of alprazolam treatment in panic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Cognitive?behavioral group treatment for social phobia: Effectiveness at five-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Brief standard self-rating for phobic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Development and validation of the Penn State Worry Questionnaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

The effectiveness of cognitive-behavior therapy for panic disorder without concurrent medication treatment: a reply to Power and Sharp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Maintenance of remission following cognitive behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Keep taking the tablets? Inadequate controls for concurrent psychotropic medication in studies of psychological treatments for panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Biofeedback treatments of generalized anxiety disorder: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Patterning of Cognitive and Somatic Processes in the Self-Regulation of Anxiety: Effects of Meditation versus Exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A comparison of biofeedback-mediated relaxation and group therapy in the treatment of chronic anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A FEAR SURVEY SCHEDULE FOR USE IN BEHAVIOUR THERAPY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Cognitive restructuring treatment: a controlled trail with anxious patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

A Rating Instrument For Anxiety Disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

Predicting prospective episodes of depression in patients with panic disorder: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021

Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021

The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021

Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021

Cognitive therapy of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021

A meta-analysis of treatments for panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0005-7894%2897%2980048-2

7 January 2021